Brepocitinib Shows Groundbreaking Results in Dermatomyositis Phase 3 Trial

Priovant Therapeutics has published results from its Phase 3 VALOR trial in the New England Journal of Medicine. The study tested brepocitinib, a potential treatment for adults with dermatomyositis, an autoimmune disease affecting muscles and skin. The findings show the drug delivered significant improvements over placebo, with experts calling the results potentially practice-changing. The VALOR trial involved 241 patients and compared brepocitinib 30 mg against a placebo. By Week 52, those receiving the drug saw a 15.3-point greater improvement in their Total Improvement Score (TIS) than the placebo group. This difference was statistically significant, with a P value of less than 0.001.

The drug also met all nine key secondary endpoints, demonstrating clinically meaningful benefits. Patients on brepocitinib were nearly twice as likely to reduce their use of background corticosteroids compared to those on placebo. However, serious infections occurred more frequently in the brepocitinib group, though all cases resolved with medical treatment.

Dr. Ruth Ann Vleugels, a dermatology specialist, highlighted the trial's potential impact on clinical practice. Meanwhile, the U.S. Food and Drug Administration (FDA) has granted Priority Review to brepocitinib's New Drug Application (NDA). A decision on approval is expected by the third quarter of 2026.

Priovant Therapeutics, a subsidiary of Roivant Sciences, focuses on developing treatments for autoimmune diseases. Brepocitinib is its lead investigational therapy, designed to address unmet needs in conditions like dermatomyositis. The VALOR trial results position brepocitinib as a promising option for dermatomyositis patients, pending FDA approval. The drug's ability to improve symptoms and reduce steroid dependence marks a notable advance in treatment. If approved, it could become the first therapy specifically indicated for this rare autoimmune condition.